Generex Biotechnology Corporation (GNBTQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Generex Biotechnology Corporation (GNBTQ) trades at $0.000001. Generex Biotechnology Corporation focuses on developing and administering large molecule drugs through oral delivery and point-of-care diagnostics. The company is currently undergoing Chapter 7 liquidation proceedings. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for GNBTQ: GNBTQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNBTQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNBTQ: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Generex Biotechnology Corporation (GNBTQ) Healthcare & Pipeline Overview
Generex Biotechnology Corporation, operating in the healthcare sector, develops oral drug delivery systems and point-of-care diagnostics. Currently under Chapter 7 liquidation, the company's portfolio includes Oral-lyn (oral insulin), AE37 (synthetic peptide vaccine), and Excellagen (wound conforming gel), targeting markets in the US and Canada.
What Is the Investment Thesis for GNBTQ?
Generex Biotechnology Corporation presents a challenging investment case due to its ongoing Chapter 7 liquidation proceedings initiated in April 2022. While the company possesses a diverse portfolio of products, including Oral-lyn, AE37, and Excellagen, the financial viability and future operations are highly uncertain. The company's negative P/E ratio and a profit margin of -1252.7% indicate significant financial distress. Potential value recovery for investors is contingent on the outcome of the liquidation process and the potential sale of assets. The company's gross margin of 78.2% suggests inherent profitability in its product lines, but this is overshadowed by its overall financial instability. Investors should exercise extreme caution and conduct thorough due diligence.
Based on FMP financials and quantitative analysis
GNBTQ Key Highlights
Gross Margin of 78.2% indicates potential profitability of the company's products before considering operating expenses.
- Chapter 7 liquidation proceedings initiated in April 2022, approved in June 2022, impacting the company's operational status.
- Development of Oral-lyn, an oral insulin product, aims to provide a non-invasive alternative to traditional insulin injections.
- AE37, a synthetic peptide vaccine, completed Phase IIb clinical trials targeting HER-2/neu oncogene expressing tumors in breast and prostate cancer.
- Profit Margin of -1252.7% reflects significant financial losses and operational challenges.
Who Are GNBTQ's Competitors?
GNBTQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNBTQ's Key Strengths?
Proprietary oral drug delivery technology.
- Diverse product portfolio including Oral-lyn and Excellagen.
- Completed Phase IIb clinical trials for AE37 vaccine.
- Established manufacturing and distribution capabilities.
What Are GNBTQ's Weaknesses?
Ongoing Chapter 7 liquidation proceedings.
- Negative profit margins and financial instability.
- Limited financial resources for research and development.
- Dependence on regulatory approvals for product commercialization.
What Could Drive GNBTQ Stock Higher?
Potential sale of assets during Chapter 7 liquidation may provide some return to creditors.
- Any positive developments in the bankruptcy proceedings could temporarily impact the stock price.
- Licensing or partnership agreements for existing technologies (unlikely given current status).
What Are the Key Risks for GNBTQ?
Chapter 7 liquidation proceedings indicate a high risk of complete loss of investment.
- Limited or no financial disclosure increases uncertainty.
- Delisting from the OTC market.
- Legal and regulatory challenges associated with bankruptcy.
What Are the Growth Opportunities for GNBTQ?
- Expansion of Point-of-Care Diagnostics: The market for rapid point-of-care diagnostics is expanding due to the increasing need for quick and accurate disease detection. Generex could potentially capitalize on this trend by expanding its range of diagnostic tests for infectious diseases, such as HIV, tuberculosis, and malaria. The global point-of-care diagnostics market is projected to reach $45.6 billion by 2027, offering a substantial growth opportunity if the company can resolve its financial issues and continue operations.
- Advancement of AE37 Vaccine: The AE37 synthetic peptide vaccine, targeting HER-2/neu expressing tumors, represents a significant opportunity in the immunotherapy space. Positive clinical trial results and regulatory approvals could drive substantial growth. The global cancer vaccine market is expected to reach $7.4 billion by 2028. However, the company's current financial situation poses a significant challenge to further development and commercialization.
- Commercialization of Excellagen: Excellagen, a wound conforming gel, addresses the growing market for advanced wound care products. Expanding its distribution network and securing partnerships with healthcare providers could drive revenue growth. The global advanced wound care market is projected to reach $12.5 billion by 2029, presenting a viable growth avenue if the company can overcome its current financial constraints.
- Oral Insulin Delivery System (Oral-lyn): The oral insulin market represents a significant opportunity for Generex, offering a non-invasive alternative to traditional insulin injections. Successful commercialization and adoption by diabetic patients could drive substantial revenue. The global insulin market is expected to reach $40 billion by 2027. However, the company faces competition from established pharmaceutical companies and regulatory hurdles.
- Development of Immunotherapeutic Products: Generex's focus on developing immunotherapeutic products and vaccines aligns with the growing interest in immunotherapy for various diseases. Investing in research and development to expand its pipeline of immunotherapeutic candidates could unlock significant growth potential. The global immunotherapy market is projected to reach $250 billion by 2028, offering a substantial opportunity for companies with innovative immunotherapeutic solutions.
What Threats Does GNBTQ Face?
- Intense competition in the biotechnology industry.
- Regulatory hurdles and lengthy approval processes.
- Product liability risks.
- Economic downturn impacting healthcare spending.
What Are GNBTQ's Competitive Advantages?
- Proprietary oral drug delivery technology.
- Patented formulations and diagnostic tests.
- Established distribution network for surgical products.
- Clinical data supporting the efficacy of its products.
What Does GNBTQ Do?
Founded in 1983 and headquartered in Miramar, Florida, Generex Biotechnology Corporation has focused on developing innovative drug delivery systems and diagnostic solutions. The company's core technology involves administering large molecule drugs through the oral cavity using a proprietary hand-held aerosol applicator. Its lead product, Generex Oral-lyn, is an oral insulin formulation intended to provide a non-invasive alternative to insulin injections. Additionally, Generex has been developing AE37, a synthetic peptide vaccine targeting HER-2/neu expressing tumors, with Phase IIb clinical trials completed for breast and prostate cancer. The company also manufactures and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, including HIV, tuberculosis, malaria, and hepatitis. These diagnostic products are available as test kits and cassettes. Furthermore, Generex offers Excellagen, a wound conforming gel, and develops immunotherapeutic products, vaccines, and an extracellular matrix hydrogel solution for ulcerative colitis. The company also manufactures and sells foot and ankle surgical kits and distributes surgical supplies and orthopedic implants. In April 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex, which was approved by the court in June 2022.
What Products and Services Does GNBTQ Offer?
- Develops oral drug delivery systems for large molecule drugs.
- Offers Generex Oral-lyn, an oral insulin product.
- Develops AE37, a synthetic peptide vaccine for breast and prostate cancer.
- Manufactures and distributes rapid point-of-care in-vitro medical diagnostics.
- Offers test kits and cassettes for infectious diseases.
- Provides Excellagen, a wound conforming gel.
- Manufactures and sells foot and ankle surgical kits.
- Distributes surgical supplies, orthopedic implants, and regenerative medicine products.
How Does GNBTQ Make Money?
- Develops and patents drug delivery technologies.
- Manufactures and sells diagnostic test kits and surgical products.
- Generates revenue through product sales and distribution agreements.
- Seeks partnerships for clinical development and commercialization of its products.
What Industry Does GNBTQ Operate In?
Generex Biotechnology Corporation operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for oral drug delivery systems and point-of-care diagnostics is growing, driven by the demand for more convenient and accessible healthcare solutions. However, Generex faces competition from established players and emerging companies developing similar technologies. The company's current liquidation status further complicates its ability to compete effectively in the market. Competitors like ALNAQ, GRYN, IMVIQ, INDR, and LHRP are also vying for market share in similar segments.
Who Are GNBTQ's Key Customers?
- Hospitals and clinics
- Diagnostic laboratories
- Surgical centers
- Distributors of medical supplies
Company Profile
Generex Biotechnology Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miramar, US. The company is led by CEO Joseph Moscato. GNBTQ has traded publicly since 1998.
Key Financial Metrics
Return on equity for Generex Biotechnology Corporation stands at 216.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -73.5%, showing how much profit it generates from its asset base. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
GNBTQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's strategic direction and potential for growth.
- Social sentiment has shifted positively, with discussions highlighting innovative product developments and potential market impact.
- Community views express optimism about upcoming partnerships that could enhance revenue streams.
- The biotech sector's overall momentum supports a favorable environment for Generex as it seeks to capitalize on emerging healthcare trends.
Bear Case
- Concerns linger about the company's financial stability, as recent reports indicate challenges in sustaining operations.
- Social media sentiment reflects skepticism regarding the timeline for product launches, with some investors voicing impatience.
- Community discussions feature bearish perspectives on competition, particularly from established players in the biotech space.
- Market perception remains cautious, with some analysts questioning the viability of Generex's business model in the current economic climate.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GNBTQ Latest News
No recent news available for GNBTQ.
GNBTQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNBTQ.
Price Targets
Wall Street price target analysis for GNBTQ.
GNBTQ MoonshotScore
What does this score mean?
The MoonshotScore rates GNBTQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Joseph Moscato
CEO
Joseph Moscato serves as the CEO of Generex Biotechnology Corporation, managing a team of 15 employees. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has been involved in various leadership roles, overseeing strategic planning, financial management, and operational execution. His expertise lies in navigating the complexities of the healthcare sector and driving innovation in drug delivery systems and diagnostics.
Track Record: Under Joseph Moscato's leadership, Generex Biotechnology Corporation has focused on advancing its pipeline of products, including Oral-lyn and AE37. He has overseen the completion of Phase IIb clinical trials for the AE37 vaccine and the expansion of the company's diagnostic product line. However, the company's recent financial challenges and Chapter 7 liquidation proceedings present a significant setback to his tenure.
GNBTQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Generex Biotechnology Corporation (GNBTQ) does not meet the minimum financial standards or reporting requirements for the higher tiers like OTCQX or OTCQB. Companies in this tier are often distressed, bankrupt, or have chosen not to comply with OTC Markets' reporting standards. Investing in OTC Other stocks carries substantial risks due to the lack of regulatory oversight and limited information available to investors. These companies may not be required to file regular financial reports with the SEC, leading to greater uncertainty and potential for fraud.
- OTC Tier: OTC Other
- Limited or no financial disclosure.
- High potential for fraud and manipulation.
- Low trading volume and liquidity.
- Significant price volatility.
- Risk of delisting and loss of investment.
- Verify the company's legal status and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's current legal and regulatory compliance.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC Other stocks.
- Company was founded in 1983.
- Has developed and marketed several products, including Oral-lyn and Excellagen.
- Completed Phase IIb clinical trials for AE37 vaccine.
- Has patents on drug delivery technologies.
Common Questions About GNBTQ (Healthcare)
What does Generex Biotechnology Corporation do?
Generex Biotechnology Corporation focuses on developing and commercializing innovative drug delivery systems and diagnostic solutions. Its primary focus has been on oral drug delivery, with its lead product, Oral-lyn, designed as an oral insulin alternative. Additionally, the company develops point-of-care diagnostics for infectious diseases and wound care products like Excellagen.
What do analysts say about GNBTQ stock?
Given Generex Biotechnology Corporation's current Chapter 7 liquidation status, formal analyst coverage is likely limited or non-existent. Key valuation metrics such as price-to-earnings ratio are not meaningful in this context due to the company's financial distress. Any historical growth considerations are overshadowed by the company's present circumstances.
What are the main risks for GNBTQ?
The primary risk for Generex Biotechnology Corporation is the ongoing Chapter 7 liquidation, which indicates a high probability of complete loss of investment. The company's financial instability, negative profit margins, and limited financial disclosure further exacerbate the risks. Additionally, there are risks associated with delisting from the OTC market and potential legal challenges related to the bankruptcy proceedings.
What are the key factors to evaluate for GNBTQ?
Evaluate GNBTQ on fundamentals, analyst consensus, and risk factors. Generex Biotechnology Corporation presents a challenging investment case due to its ongoing Chapter 7 liquidation proceedings initiated in April 2022. Not financial advice.
How frequently does GNBTQ data refresh on this page?
GNBTQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNBTQ's recent stock price performance?
Generex Biotechnology Corporation (GNBTQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary oral drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNBTQ overvalued or undervalued right now?
Generex Biotechnology Corporation (GNBTQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNBTQ before investing?
Before investing in Generex Biotechnology Corporation (GNBTQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be outdated due to the company's current status.
- The company is undergoing Chapter 7 liquidation, which significantly impacts its operations and financial viability.
- Investment in GNBTQ carries a high risk of loss.